|
1
|
Qi Y, Huang Y, Pang L, Gu W, Wang N, Hu J,
Cui X, Zhang J, Zhao J, Liu C, et al: Prognostic value of the
microRNA-29 family in multiple human cancers: A meta- analysis and
systematic review. Clin Exp Pharmacol Physiol. 44:441–454. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kwon JJ, Factora TD, Dey S and Kota J: A
systematic review of miR-29 in cancer. Mol Ther Oncolytics.
12:173–194. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sandhu R, Rivenbark AG, Mackler RM, Livasy
CA and Coleman WB: Dysregulation of microRNA expression drives
aberrant DNA hypermethylation in basal-like breast cancer. Int J
Oncol. 44:563–572. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Muluhngwi P, Alizadeh-Rad N, Vittitow SL,
Kalbfleisch TS and Klinge CM: The miR-29 transcriptome in
endocrine- sensitive and resistant breast cancer cells. Sci Rep.
7:52052017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Darbeheshti F, Rezaei N, Amoli MM,
Mansoori Y and Tavakkoly Bazzaz J: Integrative analyses of triple
negative dysregulated transcripts compared with non-triple negative
tumors and their functional and molecular interactions. J Cell
Physiol. 234:22386–22399. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shinden Y, Iguchi T, Akiyoshi S, Ueo H,
Ueda M, Hirata H, Sakimura S, Uchi R, Takano Y, Eguchi H, et al:
MiR-29b is an indicator of prognosis in breast cancer patients. Mol
Clin Oncol. 3:919–923. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Papachristopoulou G, Papadopoulos EI,
Nonni A, Rassidakis GZ and Scorilas A: Expression analysis of
miR-29b in malignant and benign breast tumors: A promising
prognostic biomarker for invasive ductal carcinoma with a possible
histotype-related expression status. Clin Breast Cancer.
18:305–312.e3. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Milevskiy MJ, Sandhu GK, Wronski A, Korbie
D, Brewster BL, Shewan A, Edwards SL, French JD and Brown MA:
MiR-29b-1-5p is altered in BRCA1 mutant tumours and is a biomarker
in basal-like breast cancer. Oncotarget. 9:33577–33588. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Drago-Ferrante R, Pentimalli F, Carlisi D,
De Blasio A, Saliba C, Baldacchino S, Degaetano J, Debono J,
Caruana-Dingli G, Grech G, et al: Suppressive role exerted by
microRNA-29b-1-5p in triple negative breast cancer through SPIN1
regulation. Oncotarget. 8:28939–28958. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
De Blasio A, Di Fiore R, Pratelli G,
Drago-Ferrante R, Saliba C, Baldacchino S, Grech G, Scerri C, Vento
R and Tesoriere G: A loop involving NRF2, miR-29b-1-5p and AKT,
regulates cell fate of MDA-MB-231 triple-negative breast cancer
cells. J Cell Physiol. 235:629–637. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang C, Bian Z, Wei D and Zhang JG:
miR-29b regulates migration of human breast cancer cells. Mol Cell
Biochem. 352:197–207. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang H, An X, Yu H, Zhang S, Tang B, Zhang
X and Li Z: MiR-29b/TET1/ZEB2 signaling axis regulates metastatic
properties and epithelial-mesenchymal transition in breast cancer
cells. Oncotarget. 8:102119–102133. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang B, Shetti D, Fan C and Wei K:
miR-29b-3p promotes progression of MDA-MB-231 triple-negative
breast cancer cells through downregulating TRAF3. Biol Res.
52:382019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kollinerova S, Vassanelli S and Modriansky
M: The role of miR-29 family members in malignant hematopoiesis.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 158:489–501.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chou J, Lin JH, Brenot A, Kim JW, Provot S
and Werb Z: GATA3 suppresses metastasis and modulates the tumour
microenvironment by regulating microRNA-29b expression. Nat Cell
Biol. 15:201–213. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vezzali F, Grassilli S, Lambertini E,
Brugnoli F, Patergnani S, Nika E, Piva R, Pinton P, Capitani S and
Bertagnolo V: Vav1 is necessary for PU.1 mediated upmodulation of
miR-29b in acute myeloid leukaemia-derived cells. J Cell Mol Med.
22:3149–3158. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Grassilli S, Brugnoli F, Lattanzio R,
Rossi C, Perracchio L, Mottolese M, Marchisio M, Palomba M, Nika E,
Natali PG, et al: High nuclear level of Vav1 is a positive
prognostic factor in early invasive breast tumors: A role in
modulating genes related to the efficiency of metastatic process.
Oncotarget. 5:4320–4336. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Grassilli S, Brugnoli F, Lattanzio R,
Marchisio M, Perracchio L, Piantelli M, Bavelloni A, Capitani S and
Bertagnolo V: Vav1 downmodulates Akt in different breast cancer
subtypes: A new promising chance to improve breast cancer outcome.
Mol Oncol. 12:1012–1025. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bertagnolo V, Grassilli S, Volinia S,
Al-Qassab Y, Brugnoli F, Vezzali F, Lambertini E, Palomba M,
Piubello Q, Orvieto E, et al: Ectopic expression of PLC-β2 in
non-invasive breast tumor cells plays a protective role against
malignant progression and is correlated with the deregulation of
miR-146a. Mol Carcinog. 58:708–721. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Grassilli S, Nika E, Lambertini E,
Brugnoli F, Piva R, Capitani S and Bertagnolo V: A network
including PU.1, Vav1 and miR-142-3p sustains ATRA-induced
differentiation of acute promyelocytic leukemia cells-a short
report. Cell Oncol (Dordr). 39:483–489. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yan B, Guo Q, Fu FJ, Wang Z, Yin Z, Wei YB
and Yang JR: The role of miR-29b in cancer: Regulation, function,
and signaling. Onco Targets Ther. 8:539–548. 2015.PubMed/NCBI
|
|
23
|
Dai X, Cheng H, Bai Z and Li J: Breast
cancer cell line classification and its relevance with breast tumor
subtyping. J Cancer. 8:3131–3141. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Brugnoli F, Lambertini E, Varin-Blank N,
Piva R, Marchisio M, Grassilli S, Miscia S, Capitani S and
Bertagnolo V: Vav1 and PU.1 are recruited to the CD11b promoter in
APL-derived promyelocytes: Role of Vav1 in modulating
PU.1-containing complexes during ATRA-induced differentiation. Exp
Cell Res. 316:38–47. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
He J, Pan Y, Hu J, Albarracin C, Wu Y and
Dai JL: Profile of Ets gene expression in human breast carcinoma.
Cancer Biol Ther. 6:76–82. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yan W, Cao QJ, Arenas RB, Bentley B and
Shao R: GATA3 inhibits breast cancer metastasis through the
reversal of epithelial-mesenchymal transition. J Biol Chem.
285:14042–14051. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Eyholzer M, Schmid S, Wilkens L, Mueller
BU and Pabst T: The tumour-suppressive miR-29a/b1 cluster is
regulated by CEBPA and blocked in human AML. Br J Cancer.
103:275–284. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lehmann BD, Bauer JA, Chen X, Sanders ME,
Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human
triple-negative breast cancer subtypes and preclinical models for
selection of targeted therapies. J Clin Invest. 121:2750–2767.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Garrido-Castro AC, Lin NU and Polyak K:
Insights into molecular classifications of triple-negative breast
cancer: Improving patient selection for treatment. Cancer Discov.
9:176–198. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lehmann BD, Jovanovic B, Chen X, Estrada
MV, Johnson KN, Shyr Y, Moses HL, Sanders ME and Pietenpol JA:
Refinement of triple-negative breast cancer molecular subtypes:
Implications for neoadjuvant chemotherapy selection. PLoS One.
11:e01573682016. View Article : Google Scholar : PubMed/NCBI
|
